Drugs / SB424323
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00240643 | Nov 2005 → Dec 2006 | atrial fibrillation | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00041509 | Jan 2002 → May 2003 | — | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB424323 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00240643 ↗ |
| Route | Oral | “500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days” NCT00041509 ↗ |